Search Results

Medicines360, a global nonprofit pharmaceutical organization specializing in women’s health, announced the appointment of Lisa David as Chair of the Board of Directors, effective January 1, 2024.

Medicines360, a mission-driven nonprofit women’s health pharmaceutical organization, announced that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately.

Medicines360 announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for treatment of Heavy Menstrual Bleeding (HMB) for up to five years in patients who choose intrauterine contraception as their method of contraception.

Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.

BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York.

Prime Medicine, Inc. announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock.

Medicines360, MSI Reproductive Choices (MSI) and Marie Stopes Kenya (MSK) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Kenya.

Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett , MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search.

Varian (NYSE: VAR) has started the installation of the cyclotron and gantry for its ProBeam® 360° single-room proton therapy system at Penn Medicine Lancaster General Health’s Ann B. Barshinger Cancer Institute.